Years ago, as I began my career in the investing world, I was introduced to a book written by famous mutual fund manager Peter Lynch, One Up on Wall Street. In it, Mr. Lynch outlined some of the methods he used to identify the stocks that helped him build the Fidelity Magellan Fund into the […]
Read MoreWith the entire country on a lockdown that most experts aren’t expecting to end quickly – even as indications are that the infection curve is indeed starting to flatten in the U.S. and cities, states, and even the federal government starting to work on plans to get the economy restarted, and to determine when the […]
Read MoreYears ago, as I began my career as an investor, I read a book by Peter Lynch. Mr. Lynch had made his name, and his fortune, as the manager of Fidelity’s flagship Magellan fund in the late 70’s and ’80’s, and his incredible performance was one of the big reasons Magellan, at the time, was […]
Read MorePlus, the White House and congressional Democrats are beginning work on a fourth stimulus package, Simon Property Group has furloughed 30% of its workers amid the coronavirus pandemic, and Domino’s shares are down after the pizza chain said sales rose less investors had expected in the first quarter.
Read MoreJust a few weeks ago – as concern about COVID-19 was rising, but hadn’t quite reached the panic stage that officially propelled the market into the first bear market in more than a decade – I profiled Tyson Foods Inc. (TSN) as a stock you should be watching. At the time, the stock had declined […]
Read MoreThe firm says these 6 stocks are their “best ideas” now.
Read MoreI had to chuckle this weekend a bit as I read some some market news reports. The market has dropped far enough that in the latter part of the week, I think investors were starting to look for reasons to start buying. Friday looked set to mark the first time in weeks the market managed […]
Read MoreThe market is in full-blown bear market mode right now, and that means that a lot of stocks have really been getting beat up since the major indices all hit new all-time highs in mid-February. As of this writing, the S&P 500 has been testing support around 2,350 quite a bit over the last couple […]
Read MoreThis morning, the market is trying to rebound from the worst single-day performance since October 1987, and certainly one of the worst weeks on record. The carnage has rippled through just about every sector of the market. I don’t think it’s too surprising, given the way coronavirus has continued to dominate practically every single headline. […]
Read MoreAs a pretty regular, retail investor, I have a lot of the same challenges most people do about tracking the stock market. Even though I do this for a living, I’m a busy guy, which means that paying attention to the entire market is hard, if not impossible to do. Like most smart investors, I’ve […]
Read MoreThe financial markets aren’t alone – or even leading the way – when it comes to reactionary, over-the-top fear about coronavirus. Last weekend, my wife and I were making our weekly run to the grocery store to stock up on the typical essentials. While this may not surprise you, it did surprise me to see […]
Read MorePlus, Boeing said it had more cancellations than new orders in February, and Pepsi is buying Rockstar Energy.
Read MoreThe market is off to a rocky start this week. Concerns about coronavirus, which continues to spread across the world and is starting to affect corporate commentary, even found a way to filter into the crude oil market. Already under pressure due to declining demand amid massive shutdowns and quarantines starting in China, but expanding […]
Read MoreThe market seems set to keep selling off – but is the story really as bad as it seems? The news continues to revolve around coronavirus-induced fear. It’s true that the spread of the virus continues to get bigger; but there are also indications that the worst effects may have already begun tapering off. I […]
Read MorePlus, 30-year mortgage rates have fallen to their lowest level ever amid coronavirus fears, and an analyst says Gilead’s COVID-19 treatment only has a 50/50 chance, at best, of proving successful.
Read More